Loading patent…
AssigneeGradient
InventorsAlain Friboulet, Berangere Avalle-Bihan, Helene Debat, Daniel Thomas
Estimating the term…
The invention concerns novel compounds capable of modulating the activity and stimulating the production of catalytic antibodies. More particularly, the invention concerns a compound capable of increasing the activity of an antibody having specific affinity for the catalytic site of the antibody, and it is not immunogenic. Such compounds are useful in particular for therapeutic treatment or prevention of a pathology related to an enzymatic deficiency, to stimulate in vivo hydrolysis of xenobiotics, drugs, medicines or any other molecule potentially toxic for the organism or for preventing or inhibiting allergic reactions.
A compound capable of modulating the activity of a catalytic antibody, said compound being characterized in that it has a specific affinity for the catalytic site of said antibody, and in that it is non immunogenic.
A compound according to any one of the preceding claims, characterized in that it comprises a non immunogenic peptide derived from an epitope of the Herpes virus.
A compound that can increase, in vivo, the physiological level of an enzymatic activity, characterized in that it comprises a non immunogenic substrate of a catalytic antibody having said enzymatic activity or one of its activator or inhibitor analogues, and in that it has a specific affinity for the catalytic site of said antibody.
A compound that can stimulate the hydrolysis of potentially toxic xenobiotics in vivo by specific catalytic antibodies, characterized in that it is non immunogenic, it comprises a recalcitrant and potentially toxic xenobiotic or a fragment thereof and in that it has a specific affinity for the catalytic site of said antibody.
A compound that can stimulate, in vivo, the degradation of drugs or medication by specific catalytic antibodies, characterized in that it is non immunogenic, in that it comprises a drug or a medication or a fragment or analogue thereof and in that it has a specific affinity for the catalytic site of said antibody.
A compound for preventing or diminishing an allergic reaction linked to an allergen, characterized in that it comprises a non immunogenic analogue of said allergen and in that it has a specific affinity for the catalytic site of said antibody.
Dependencies are inferred from the claim text.